Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PURE BiosciencePURE -2.28% Earnings Yield (Joel Greenblatt) % is -12.52% as of Apr. 2026. The stock has 5 warning signs investors should review. Among 2,028 Consumer Packaged Goods companies, PURE Bioscience ranks worse than 93% on this metric.
PURE Bioscience's Enterprise Value for the quarter that ended in Apr. 2026 was $14.50 Mil.
PURE Bioscience's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 was $-1.82 Mil. PURE Bioscience's Earnings Yield (Joel Greenblatt) for the quarter that ended in Apr. 2026 was -12.52%.
The historical rank and industry rank for PURE Bioscience's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
PURE'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -52.68 Med: -19.69 Max: 1.91
Current: -13.62
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of PURE Bioscience was 1.91%. The lowest was -52.68%. And the median was -19.69%.
PURE's Earnings Yield (Joel Greenblatt) % is ranked worse than 93% of 2028
companies
in the Consumer Packaged Goods industry
Industry Median: 6.05
vs PURE: -13.62
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. PURE Bioscience's Forward Rate of Return (Yacktman) % for the quarter that ended in Apr. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
PURE Bioscience (OTCPK:PURE) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
PURE Bioscience Earnings Yield (Joel Greenblatt) % Related Terms
PURE Bioscience Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for PURE Bioscience's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience Earnings Yield (Joel Greenblatt) % Chart
PURE vs DQWS, TANH, DSY: Earnings Yield (Joel Greenblatt) % Comparison
For the Household & Personal Products subindustry, PURE Bioscience's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PURE Bioscience Earnings Yield (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where PURE Bioscience's Earnings Yield (Joel Greenblatt) % falls into.
PURE Bioscience Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
PURE Biosciences Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jul. 2025 is calculated as
PURE Bioscience's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -12.52% mean?
PURE Bioscience (PURE) has a Earnings Yield (Joel Greenblatt) % of -12.52% as of Apr. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on PURE Bioscience and its competitors. According to the industry distribution chart, PURE Bioscience ranks #1886 out of 2028 companies in the Consumer Packaged Goods industry, placing it in the top 93%.
Is PURE Bioscience's Earnings Yield (Joel Greenblatt) % too high?
PURE Bioscience's current Earnings Yield (Joel Greenblatt) % is -12.52%. Based on the distribution chart, PURE Bioscience ranks #1886 out of 2028 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers.
How does PURE Bioscience's Earnings Yield (Joel Greenblatt) % compare to DQWS and TANH?
According to the Consumer Packaged Goods industry distribution chart, PURE Bioscience ranks #1886 out of 2028 companies for Earnings Yield (Joel Greenblatt) %. This places PURE Bioscience in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 6.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median Earnings Yield (Joel Greenblatt) % among Consumer Packaged Goods companies is 6.05, based on 2,028 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on PURE Bioscience and its competitors. For the Consumer Packaged Goods industry, the median Earnings Yield (Joel Greenblatt) % is 6.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PURE Bioscience's current Earnings Yield (Joel Greenblatt) % is -12.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PURE Bioscience stock overvalued right now?
Based on GuruFocus' analysis, PURE Bioscience (PURE) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.06 — trading 40% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -12.52%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For PURE Bioscience (PURE), the current Earnings Yield (Joel Greenblatt) % is -12.52% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PURE has been successfully added to your 
